|本期目录/Table of Contents|

[1]武大伟综 述,李常颖审 校.新生抗原与个体化肿瘤免疫治疗[J].天津医科大学学报,2019,25(01):94-96.
点击复制

新生抗原与个体化肿瘤免疫治疗(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
25卷
期数:
2019年01期
页码:
94-96
栏目:
综述
出版日期:
2019-01-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2019)01-0094-03
作者:
武大伟1综 述; 李常颖2审 校
（1.天津医科大学第二医院检验科，天津 300211；2.天津市泌尿外科研究所，天津 300211）
Author(s):
-
关键词:
新生抗原; 肿瘤免疫治疗; 细胞免疫治疗
Keywords:
-
分类号:
R730.5
DOI:
-
文献标志码:
A
摘要:
新生抗原（neoantigen）是一种位于肿瘤细胞表面的特异性抗原，是肿瘤基因突变的产物，这种突变在正常细胞中不存在。过去几年的研究表明新生抗原在肿瘤免疫治疗中起着关键作用，新生抗原的识别筛选和鉴定加速了肿瘤患者个体化免疫治疗的发展，终将使更多患者受益。
Abstract:
-

参考文献/References:


[1] Stronen E, Toebes M, Kelderman S, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires[J]. Science,2016,352(6291):1337
[2] Schumacher T N, Schreiber R D. Neoantigens in cancer immunotherapy[J]. Science, 2015,348(6230):69
[3] De Plaen E, Lurquin C, Van Pel A, et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation[J]. Proc Natl Acad Sci USA, 1988, 85(7):2274
[4] Monach P A, Meredith S C, Siegel C T, et al. A unique tumor antigen produced by a single amino acid substitution[J]. Immunity, 1995, 2(1):45
[5] Rooney M S, Shukla S A, Wu C J, Molecular and genetic properties of tumors associated with local immune cytolytic activity[J]. Cell, 2015, 160(1/2):48
[6] Brown S D, Warren R L, Gibb E A, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival[J]. Genome Res, 2014, 24(5):743
[7] Giannakis M, Mu X J, Shukla S A, et al. Genomic correlates of immunecell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 15(4):857
[8] Howitt B E, Shukla S A, Sholl L M, et al. Association of polymerase emutated and icrosatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1[J]. JAMA Oncol, 2015, 1(9):1319
[9] Yap K L, Kiyotani K, Tamura K, et al. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival[J]. Clin Cancer Res, 2014, 20(24):6605
[10] Choudhury N J, Kiyotani K, Yap K L, et al. Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer[J]. Eur Urol Focus, 2015, 2(4):445
[11] Kiyotani K, Park J H, Inoue H, et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma[J]. Oncoimmunology, 2017, 6(2):e1278330
[12] Kato T, Park J H, Kiyotani K, et al. Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers[J]. Oncotarget, 2017, 8(37):62029
[13] Rosenberg S A, Restifo N P. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230):62
[14] Robbins P F, Kassim S H, Tran T L, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response[J]. Clin Cancer Res, 2014, 21(5):1019
[15] Robbins P F, Morgan R A, Feldman S A, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J]. J Clin Oncol, 2011, 29(7):917
[16] Rapoport A P, Stadtmauer E A, Binder-Scholl G K, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma[J]. Nat Med, 2015, 21(8):914
[17] Nguyen L T, Ohashi P S. Clinical blockade of PD1 and LAG3--potential mechanisms of action[J]. Nat Rev Immunol, 2015, 15(1):45
[18] Gubin M M, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J]. Nature, 2014, 515(7528):577
[19] Le D T, Uram J N, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372(26):2509
[20] Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma[J]. N Engl J Med, 2014, 371(23):2189
[21] Van Allen E M, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma[J]. Science, 2015, 350(6257):207
[22] Rizvi N A, Hellmann M D, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230):124
[23] Rosenberg S A, Yang J C, Sherry R M, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy[J]. Clin Cancer Res, 2011, 17(13):4550
[24] Robbins P F, Lu Y C, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells[J]. Nat Med, 2013, 19(6):747
[25] Lu Y C, Yao X, Crystal J S, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions[J]. Clin Cancer Res, 2014, 20(13):3401
[26] Yoshitake Y, Fukuma D, Yuno A, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS[J]. Clin Cancer Res, 2014;21(2):312
[27] Okuno K, Sugiura F, Inoue K, et al. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer[J]. Anticancer Res, 2014, 34(6):3045
[28] Hazama S, Nakamura Y, Tanaka H, et al. A phase IotaI study of five peptides combination with oxaliplatin-based chemotherapy as a firstline therapy for advanced colorectal cancer (FXV study)[J]. J Transl Med, 2014, 12(1):108
[29] Coulie P G, Van den Eynde B J, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy[J]. Nat Rev Cancer, 2014, 14(2):135
[30] Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184):641
[31] Tran E, Robbins P F, Lu Y C, et al. T-cell transfer therapy targeting mutant KRAS in cancer[J]. N Engl J Med, 2016, 375(23):2255
[32] Ott P A, Hu Z, Keskin D B, et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature, 2017, 547(7662):217
[33] Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature, 2017, 547(7662):222
[34] Rosenberg S A, Restifo N P. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230):62
[35] Morgan R A, Dudley M E, Wunderlich J R, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes[J]. Science, 2006, 314(5796):126
[36] Robbins P F, Morgan R A, Feldman S A, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J]. J Clin Oncol, 2011, 29(7):917
[37] Rapoport A P, Stadtmauer E A, Binder-Scholl G K, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma[J]. Nat Med, 2015, 21(8):914
[38] Leisegang M, Engels B, Schreiber K, et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation[J]. Clin Cancer Res, 2015, 22(11):2734
[39] Leisegang M, Kammertoens T, Uckert W, Blankenstein T. Targeting human melanoma neoantigens by T cell receptor gene therapy[J]. J Clin Invest, 2016, 126(3):854

相似文献/References:

备注/Memo

备注/Memo:

作者简介 武大伟（1982-），女，主管技师，硕士，研究方向：临床生物化学；通信作者：李常颖，E-mail: chyingli2011@163.com。
更新日期/Last Update: 2019-03-01